Table 1

Characteristics of the included seven studies

Study	Study design	NCT trial no.	Patients	Sample size (patient)	Mean age (year)	Sex (M/F)	Intervention groups	Follow-up (months)
MYRROR28	RCT	01249664	Subfoveal or juxtafoveal CNV secondary to high myopia	121	58.2±13.3	29/92	IVA (2.0 mg); Sham (no drug)	12
Parodi et al29	RCT	None	Juxtafoveal CNV secondary to pathological myopia	37	49.45	13/24	IVB (1.25 mg); SF PDT (50 J/cm²)	24
Ruiz-Moreno et al30	RCT	00967850	Subfoveal and/or juxtafoveal CNV secondary to pathological myopia	42	None	None	IVB (1.25 mg); SF PDT (50 J/cm²)	24
RADIANCE²¹	RCT	01217944	Subfoveal or juxtafoveal or extrafoveal CNV secondary to pathological myopia	276	55.56±13.96	68/209	IVR (0.5 mg): guided by VA stabilisation; IVR (0.5 mg): guided by disease activity; SF PDT (50 J/cm²)	12
BRILLIANCE²²	RCT	01922102	Subfoveal or juxtafoveal or extrafoveal CNV secondary to pathological myopia	457	51.2±12.7	146/311	IVR (0.5 mg): guided by VA stabilisation; IVR (0.5 mg): guided by disease activity; SF PDT (50 J/cm²)	12
Saviano et al31	RCT	None	Subfoveal or juxtafoveal CNV secondary to pathological myopia	34	62.4	8/26	IVB (1.25 mg); IVB (1.25 mg)+RF PDT*	12
Rinaldi et al32	RCT	01968486	Subfoveal or juxtafoveal CNV secondary to pathological myopia	40	44.6±4.48	19/21	IVR (0.5 mg); IVR (0.5 mg)+ RF PDT (25 J/cm²)	12

anti-VEGF, anti-vascular endothelial growth factor; CNV, choroidal neovascularisation; IVA, intravitreal aflibercept; IVB, intravitreal bevacizumab; IVR, intravitreal ranibizumab; M/F, male/female; NCT, national clinical trial; RF PDT, reduced fluence photodynamic therapy; SF PDT, standard fluence photodynamic therapy; PDT, photodynamic therapy; RCT, randomised controlled trial; VA, visual acuity.